Plasma HER2 levels are not associated with cardiac function or hypertrophy in control subjects and heart failure patients.
A proper interaction between the endocardial-derived ligand Neuregulin-1 and the myocardial "Human Epidermal growth factor Receptor 2" (HER2) is essential for maintaining heart function. The shed extracellular domain (ECD) of HER2 circulates in blood and serves as a surrogate marker for breast cancer. Altered cardiac loading conditions are accompanied by dysregulation of the myocardial HER2 gene expression. We studied 193 controls with preserved ejection fraction (EF>55%) and 572 patients with different degrees of systolic heart failure: 98 had EF 45-55%, 138 patients EF 35-44%, and 336 patients, EF <35%, respectively. The corresponding mean HER2 levels were 6.44 ± 0.46 ng/mL, 6.07 ± 0.76 ng/mL and 6.57 ± 0.87 ng/mL, and 6.17 ± 0.71 ng/mL, respectively. Furthermore, there was no significant association between plasma HER2 levels and left ventricular filling pressures or the left ventricular wall thickness. The HER2 plasma levels do not reflect the cardiac function and are therefore not useful as a biomarker for heart failure.
Posch
Maximilian G
MG
Panek
Anna
A
Kersten
Andrea
A
Ghadge
Santhosh Kumar
SK
Geier
Christian
C
Richter
Silke
S
Perrot
Andreas
A
Gailani
Mudather
M
Dietz
Rainer
R
Lüftner
Diana
D
Ozcelik
Cemil
C
D000368:Aged; D015415:Biomarkers / Q000097:blood; D005260:Female; D006333:Heart Failure / Q000097:blood* / Q000503:physiopathology; D006334:Heart Function Tests; D006801:Humans; D017379:Hypertrophy, Left Ventricular / Q000097:blood* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000097:blood*
D015415:Biomarkers; D018719:Erb-b2 Receptor Tyrosine Kinases; C508053:ERBB2 protein, human